|
Originally published In Press as doi:10.1074/jbc.M106811200 on August 3, 2001
J. Biol. Chem., Vol. 276, Issue 48, 45207-45216, November 30, 2001
Hematopoietic Progenitor Kinase 1 Associates
Physically and Functionally with the Adaptor Proteins B Cell Linker
Protein and SLP-76 in Lymphocytes*
Karsten
Sauer §¶,
Jen
Liou¶ ,
Suresh B.
Singh**,
Deborah
Yablonski ,
Arthur
Weiss §§, and
Roger M.
Perlmutter§¶¶
From the § Department of Immunology and Rheumatology and
** Department of Molecular Systems, Merck Research
Laboratories, Rahway, New Jersey 07065, the Department of
Medicine and Department of Microbiology and Immunology, Howard Hughes
Medical Institute, University of California, San Francisco, California
94143, and the  Department of Pharmacology,
Rappaport Faculty of Medicine, Technion-Israel Institute of Technology,
POB 9649 Bat Galim, Haifa 31096, Israel
Received for publication, July 19, 2001
 |
ABSTRACT |
B cell linker protein (BLNK) is a SLP-76-related
adaptor protein essential for signal transduction from the BCR. To
identify components of BLNK-associated signaling pathways, we performed a phosphorylation-dependent yeast two-hybrid analysis using
BLNK probes. Here we report that the serine/threonine kinase
hematopoietic progenitor kinase 1 (HPK1), which is activated upon
antigen-receptor stimulation and which has been implicated in the
regulation of MAP kinase pathways, interacts physically and
functionally with BLNK in B cells and with SLP-76 in T cells. This
interaction requires Tyr379 of HPK1 and the
Src homology 2 (SH2) domain of BLNK/SLP-76. Via homology
modeling, we defined a consensus binding site within ligands for SLP
family SH2 domains. We further demonstrate that the SH2 domain of
SLP-76 participates in the regulation of AP-1 and NFAT
activation in response to T cell receptor (TCR) stimulation and
that HPK1 inhibits AP-1 activation in a manner partially dependent on
its interaction with SLP-76. Our data are consistent with a model in
which full activation of HPK1 requires its own phosphorylation on
tyrosine and subsequent interaction with adaptors of the SLP family,
providing a mechanistic basis for the integration of this kinase into
antigen receptor signaling cascades.
 |
INTRODUCTION |
The most proximal events following the stimulation of lymphocyte
antigen receptors are the activation of Src family (Lck, Lyn, and Fyn)
and Syk family (Syk and ZAP-70) protein-tyrosine kinases
(PTKs).1 Many of the
substrates of these PTKs are adaptor proteins composed of modular
domains, which mediate various types of protein-protein interactions
(1-6). For example, the reversible phosphorylation of tyrosine
residues creates transient binding surfaces for SH2 or PTB domains (7).
Thus, phosphotyrosine interactions allow the dynamic modulation of
signaling complexes.
In T cells, tyrosine phosphorylation of the palmitoylated transmembrane
protein LAT is critical for signaling from the TCR, because it allows
the SH2/PTB domain-mediated recruitment of signal transducers like
PLC 1, Shb, and Grb2 adaptors (Gads, Grb2 and Grap) (3) into
proximity with the TCR within glycosphingolipid-enriched membrane
microdomains (3-6, 8). Through independent interactions with their SH3
domains, Grb2 adaptors recruit several other signal transducers,
including Cbl, p85PI3K, HPK1, Sos, and SLP-76 (3, 4,
9-12). These interactions are required for activation of the Ras
pathway and the elevation of intracellular calcium, ultimately leading
to the activation of transcription factors like AP-1 and NFAT. In
particular, gene disruption studies demonstrate that SLP-76 is
essential for T cell development and assists in linking TCR signaling
to activation of PLC 1, Ras, and Erk (13-15). These functions rely
on dynamic associations of tyrosine-phosphorylated SLP-76 with the
SH2 domains of Itk, Vav, and Nck (3, 6). SLP-76 itself also possesses an SH2 domain for which only one ligand has been identified so far,
SLAP-130/FYB (16, 17). Upon TCR stimulation, SLAP-130 is phosphorylated
on tyrosine and subsequently binds to SLP-76, thereby modulating the
TCR-induced signaling cascade (16-21).
While most cytoplasmic components implicated in TCR signaling have
direct counterparts in B cells, no functional analog of LAT has been
identified in B cells, and the mechanism mediating recruitment of
Grb2-family members to the B cell receptor (BCR) complex remains
enigmatic. Although LAT is not expressed in B cells (6), B lymphocytes
do contain a relative of SLP-76, BLNK/SLP-65/BASH (hereafter referred
to as BLNK; Fig. 1A) (22-24). BLNK undergoes Syk-dependent tyrosine phosphorylation and is recruited
into glycosphingolipid-enriched membrane microdomains upon BCR
stimulation (1, 25-27). Prior studies demonstrated that BLNK is
essential for BCR-induced Erk, JNK, and p38 activation, PLC 2
activation, IP3 production, Ca2+ mobilization,
up-regulation of CD69 and CD86/B7-2, proliferation, and B cell
development (28-33). Importantly, BLNK undergoes molecular interactions characteristic of those documented for both LAT and SLP-76
(25). Following its tyrosine phosphorylation, the N-terminal domain of
BLNK binds to the SH2 domains of Vav, Nck, Btk (the B cell Itk
homolog), PLC 2, and Cbl (22, 26, 27, 34). BLNK also contains
proline-rich regions that recruit Grb2 adaptors. While these
interactions explain some of the functions of BLNK, it is still unknown
how BLNK connects the BCR to activation of JNK and p38.
BLNK harbors an SH2 domain at its C terminus, for which no
functional ligands have been identified (3). To explore the functions
of the BLNK SH2 domain, we employed a Syk-driven yeast two-hybrid
screen, which could identify novel
phosphotyrosine-dependent binding partners for BLNK in B
cells. Such molecules could provide links between BLNK and the JNK or
p38 pathways. We isolated multiple interactors for BLNK baits,
including Gads, Vav, and the serine/threonine kinase HPK1 (35, 36).
Interestingly, HPK1 has been shown to be activated upon antigen
receptor stimulation, whereupon it acts as a regulator of MAP kinase
pathways (9, 10). We show that HPK1 and SLP-76 can be efficiently
co-immunoprecipitated from lysates of TCR-stimulated, but not
unstimulated, Jurkat cells. This interaction requires
Tyr379 of HPK1 and the SLP-76 SH2 domain in cotransfected
J14 cells. Moreover, full activation of HPK1 is dependent on both
Tyr379 of HPK1 and an intact SLP-76 SH2 domain. In
cotransfection experiments with SLP-76-deficient J14 cells (13), we
demonstrate that the SLP-76 SH2 domain participates in the regulation
of AP-1 and NFAT activation in response to TCR stimulation. Finally,
HPK1 acts as a dose-dependent inhibitor of AP-1 activation,
and full inhibitor activity is dependent on Tyr379 of HPK1
and an intact SLP-76 SH2 domain. Our results suggest that full
activation of HPK1 in response to antigen receptor stimulation requires
both tyrosine phosphorylation of HPK1 and its subsequent interaction
with the SH2 domains of SLP-76 (in T cells) or BLNK (in B cells). Thus,
HPK1 acts in part to connect SLP family adaptors to mitogen-activated
protein kinase signaling and the negative regulation of AP-1
activation in lymphocytes.
 |
EXPERIMENTAL PROCEDURES |
DNA Constructs, Reverse Transcription PCRs, and Site-directed
Mutageneses--
We based our Syk-driven yeast
two-hybrid system on the MATCHMAKER LexA Two-hybrid System
(CLONTECH Laboratories, Inc., Palo Alto, CA). To
generate a bait vector that allows coexpression of a bait and Syk as a
driver kinase, we inserted a cDNA fragment encoding murine Syk into
the Gal-inducible expression cassette of pYES2 (NT 1-876; Invitrogen,
Inc., San Diego, CA) and subcloned the Syk expression cassette into the
unique NruI site of pLexA, generating pLexASyk. Grb2
SH2(R85K) was generated via PCR mutagenesis. Full-length murine
BLNK was obtained via reverse transcriptase-PCR from mouse spleen
poly(A+) RNA. The R373K mutation was introduced via PCR
mutagenesis. Identity and sequence of all constructs were confirmed via
automated DNA sequence analysis. Target cDNA libraries in pB42AD
were constructed using the Two-hybrid cDNA Library Construction Kit
(CLONTECH) following the user manual. We used
double oligo(dT)-purified mouse spleen or human bone marrow
poly(A+) RNA (CLONTECH), or prepared
our own triple oligo(dT)-purified poly(A+) RNA from
thymocytes of 6-9-week-old C57BL/6 mice using FastTrack 2.0 kits
(Invitrogen). 50% of each cDNA were random- or oligo(dT)-primed, pooled, and size-selected to exclude cDNAs of less than 500 base pairs. Each library represents >1.4 × 106
independent clones and contains at least 76% recombinant clones with
average insert sizes of 0.7-0.8 kb. pEF-BOS, pEF/flag/SLP-76 WT,
pEF/flag/SLP-76 R448K, and pCDEF-HPK1:HA have been described (9, 37).
pCDEF-HPK1(YF):HA was generated via standard PCR mutagenesis methods.
Yeast Two-hybrid Screens and Analyses--
Yeast handling,
analyses, and plasmid DNA isolation were carried out as described in
the MATCHMAKER LexA Two-hybrid System user manual or the
CLONTECH yeast protocols handbook. Yeast
transformations were performed with the Yeastmaker yeast transformation
system (CLONTECH). Yeast cell protein extracts were
analyzed via immunoblotting with m -LexA, m -BLNK, or 4G10
antibodies for the presence and abundance of bait proteins or Syk or
Syk activity. Two-hybrid screens were performed on inducing selection
agar containing X-gal (-H-U-T-L/GR/X) for up to 10 days, and
single candidate positive colonies were restreaked onto the same medium
for further purification and propagation. For restriction endonuclease
mapping, inserts of isolated target cDNA clones were amplified via
PCR. Representatives for each class, defined by a unique restriction
pattern, were sequenced and subjected to further analysis.
Homology Modeling and Data Base Searches--
Homology models
for the SH2 segments were based on the sequence alignment shown in Fig.
7A. Various SLP adaptor sequences were modeled into the SH2
domain taken from the crystal structure of full-length Src, with ligand
peptides modeled into the Src C-terminal peptide bound to the Src SH2
domain (38). A cartesian average of 10 intermediate homology models was
subjected to steepest descent minimization to obtain the nearest
approximation to the starting model. Modeling was performed using MOE
version 2000.02 (Chemical Computing Group, Montreal, Canada). Backbone
structures of human Src and hBLNK were rendered with RIBBONS (M. Carson, University of Alabama at Birmingham).
Antibodies and Immunoblot Analyses--
Immunoprecipitations and
immunoblots were performed using the following antibodies: sheep
anti( )-human SLP-76 (gift from G. Koretzky, University of
Pennsylvania, Philadelphia, PA); rabbit -HPK1 (9) or -HPK1 (N-19;
Santa Cruz Biotechnology, Inc., Santa Cruz, CA); -HA, clone 3F10
(Roche Molecular Biochemicals); -FLAG, clone M2 (Sigma);
m -phosphotyrosine, clone 4G10 (Upstate Biotechnology, Inc., Lake
Placid, NY); and m -LexA (CLONTECH). For
co-immunoprecipitation studies, antibodies were prebound to protein A + G-agarose beads (Santa Cruz Biotechnology). Immunoblot analyses were
performed using ECL or ECF (Amersham Pharmacia Biotech) with
quantification on a STORM system (Molecular Dynamics, Inc., Sunnyvale, CA).
T and B Cell Stimulation, Lysate Preparation, and
Co-immunoprecipitations--
Jurkat or J14 cells were kept in
phosphate-buffered saline (154 mM NaCl, 10 mM
sodium phosphate, pH 7.4) or stimulated either with C305 (anti-Jurkat
Ti -chain monoclonal antibody) as described in Ref. 9, or with 2 µg of UCHT1 (anti-human CD3 monoclonal antibody, BD Pharmingen)/OKT4
in phosphate-buffered saline/8 × 107 cells/ml
followed by goat anti-mouse IgG cross-linking for 3 min at 37 °C,
lysed by the addition of 1/4 volume of 5× YNP/PI (250 mM Tris-HCl, pH 8.0, 134 mM NaCl, 5% Nonidet
P-40, 100 mM NaF, 1.5 mM
Na3VO4, 0.1% NaN3, 2.9 mM phenylmethylsulfonyl fluoride, 5 µg/ml pepstatin A, 5 µg/ml aprotinin, 10 µg/ml leupeptin, 0.5 mg/ml TPCK, 50 µg/ml
soybean trypsin inhibitor; all from Sigma) and rocking at +4 °C for
30 min. Extracts were prepared and precleared with 10 µg of normal
sera. Input extracts were denatured by the addition of 1/2 volume of 3× sample buffer and boiling. For co-immunoprecipitations, extracts corresponding to 2-9 × 107 cells were
rotated at +4 °C with 4-20 µg of the respective antibody. After
washing in Y-NP40 (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% Nonidet P-40, 20 mM NaF, 0.3 mM Na3VO4, 0.02%
NaN3), precipitated proteins were eluted by boiling in 3×
sample buffer.
Cell Transfections, HPK1 Kinase Assays, and Reporter Gene
Assays--
Cell transfections, HPK1 kinase assays, and AP-1 or
NFAT-luciferase reporter gene assays were performed as described in
Ref. 9, except that pNFAT-TA-Luc (CLONTECH) or
pGL-2E-Luc (39) was used for NFAT reporter assays, and luciferase
assays were performed with LucLite Plus kits (Packard). J14 lines
stably reconstituted with various SLP-76 mutants (described in detail
in Ref. 40) were maintained in RPMI 1640 medium supplemented with 5%
fetal calf serum, penicillin, streptomycin, and glutamine. Cells were stimulated with C305 or stimulated with UCHT1 alone or in combination with OKT4 ascites fluid and CD28.2 (BD Pharmingen) followed by cross-linking with goat anti-mouse IgG (Jackson).
 |
RESULTS |
Isolation of Novel BLNK Interactors in a Syk-dependent
Yeast Two-hybrid Screen--
We employed a modified yeast two-hybrid
screen strategy to search for novel
phosphotyrosine-dependent and -independent interactors that
bind full-length BLNK (Fig.
1A). BLNK was co-expressed
with murine Syk and used to screen various cDNA-libraries. We
isolated 116 reproducibly positive clones from 1.6 × 108 colony-forming units of an amplified murine
spleen cDNA library representing ~1.9 × 106
independent clones. The isolates represented three classes of cDNAs. Class 1 (111 clones) encodes the C-terminal SH3 domain of
murine Gads (Fig. 1B). Class 2 (two clones) represents a Vav cDNA fragment including the SH2 and C-SH3 domains (Fig.
1B, clone 37) (41). Class 3 (three clones) represents
two distinct but overlapping cDNA fragments encoding internal
regions of murine HPK1 (Fig. 1B, clones 82 and 103). Both
fragments include Tyr379, a potential tyrosine
phosphorylation site, and one (clone 103) or three (clone 82) of the
proline-rich stretches flanking Tyr379 (35, 36).
Representatives of all classes were subsequently tested for
interactions with positive or negative control baits (Fig.
1C). While the Gads isolate showed a strong, constitutive, Syk-independent interaction with BLNK, mHPK1 isolates interacted strongly with BLNK only in the presence of Syk. The BLNK R373K mutant,
which is expected to have a reduced phosphotyrosine binding capability
based on its analogy to the SLP-76 R448K mutant (37), interacted only
weakly with HPK1 clones 82 and 103. Moreover, no interaction occurred
when a mutant HPK1 construct was used, in which Tyr379 was
replaced by phenylalanine. Likewise, the interaction was abrogated in
the absence of Syk. In control analyses, BLNK baits did not interact
with LAT or Grb2 SH2 domain targets, and Lck SH2 domain or Lamin baits
did not interact with any target (data not shown). These results
suggest that HPK1 and BLNK can interact when coexpressed in the
presence of Syk and that this interaction requires an intact BLNK SH2
domain and Tyr379 of HPK1.

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 1.
Isolation of HPK1 as a BLNK SH2 domain
interactor. A, structure of BLNK which was used as a
bait in the presence of Syk. B, structures of BLNK
interactors isolated in our screen. For comparison, the modular
structures of full-length HPK1, Vav, and Gads are depicted
schematically above schemes of representative target
isolates. Y, tyrosine residues involved in SH2 domain
interactions. Pro-rich and
P1-P4, proline-rich regions.
SH2 and SH3, SH2 and SH3 domains, respectively.
CNH, citron homology domain (76). CH, calponin
homology domain. ac., acidic region. DH, Dbl
homology domain. PH, pleckstrin homology domain.
C, two-hybrid interaction analyses in the presence (+) or
absence ( ) of murine Syk. Baits were wild type mBLNK
(BLNK) or the mBLNK R373K mutant (BLNK
[R373K]). Targets were wild type mHPK1
isolate 103 (mHPK1#103), the Y379F mutant version of 103 (mHPK1#103(YF)), a representative murine Gads isolate
(mGads), a mLAT-C fragment isolated in screens with
Grb2(SH2) baits (mLAT-C), and the Grb2 SH2 domain as a
negative control target (Grb2(SH2)). Tester strains were
streaked onto either induction/selection medium containing X-gal
(-H-U-T-L/GR/X) or a noninducing, nonselective medium (-H-U-T)
for loading controls. Similar results were found for both HPK1 isolates
82 and 103 (data not shown). Three independent experiments involving
independently derived yeast tester strains yielded virtually identical
results.
|
|
Therefore, further study focused on HPK1 as a potential mediator of SLP
adaptor signaling. In particular, although the Vav isolates from our
screen interacted with wild type BLNK in the presence of Syk,
interactions of varying intensities were also observed in the absence
of Syk (data not shown). The variability of this interaction in yeast
most likely reflects its overall low avidity and in any case rendered
further studies impossible.
Association of HPK1 and SLP-76 in T Cells--
HPK1 has recently
been implicated in signal transduction from antigen receptors (9, 10).
Engagement of BCR or TCR results in activation of HPK1. This activation
was strongly reduced in B cells lacking BLNK or in T cells lacking
SLP-76 (9). A possible explanation would be that molecular interactions
with SLP adaptors are required for full activation of HPK1 in both B
cells and T cells. To test if HPK1 associates with SLP-76 in T cells,
we immunoprecipitated SLP-76 from lysates of unstimulated or
anti-TCR-stimulated Jurkat cells, or SLP-76-deficient J14 cells as
specificity controls, and visualized co-precipitating proteins on
immunoblots (Fig. 2A). HPK1
could readily be detected in SLP-76 immunoprecipitates from
anti-TCR-stimulated Jurkat cells but not in precipitates from
unstimulated cells containing equal amounts of SLP-76 or in
precipitates from J14 cells. Prolonged exposure of the blot permitted
visualization of a weak HPK1 signal in anti-SLP-76 precipitates from
unstimulated Jurkat cells, probably reflecting a weak basal association
between HPK1 and SLP-76, which could be mediated by Grb2/Gads (data not
shown). Stripping and reprobing of the completely stripped blot with an
anti-phosphotyrosine antibody revealed that the SLP-76-associated HPK1
was possibly tyrosine-phosphorylated. In addition, a protein most
likely representing tyrosine-phosphorylated LAT (pp36-38)
co-precipitated with SLP-76. No co-precipitation of LAT was found in
lysates from SLP-76-deficient cells. The presence of a weak band in
precipitates from unstimulated cells (lane 3) could reflect a participation of LAT in basal interactions with SLP-76.
The presence of tyrosine-phosphorylated proteins with similar mobility
as SLP-76 and LAT could be demonstrated, albeit at low intensity, in
HPK1 precipitates from lysates of ConA-stimulated Jurkat cells and
normal murine thymocytes (data not shown). Taken together, these
results demonstrate that TCR stimulation induces the molecular
interaction of SLP-76 and HPK1 in a complex that may also include
tyrosine-phosphorylated LAT.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 2.
TCR stimulation induces the association of
SLP-76 and HPK1 in a manner dependent on Tyr379 of HPK1 and
the SLP-76 SH2 domain. A, Jurkat cells or
SLP-76-deficient J14 cells were stimulated with anti-TCR antibody C305
for 2 min, lysed, and subjected to immunoprecipitation (IP)
with polyclonal antibodies against human SLP-76. Lysates representing
1 × 106 cells or IP eluates representing 9 × 107 cells with (+) or without ( ) stimulation were
separated by SDS-polyacrylamide gel electrophoresis and subjected to
immunoblot analysis with antibodies against HPK1 or human SLP-76
followed by ECL detection. Subsequently, the blots were stripped and
reprobed with antibody 4G10 against phosphotyrosine
(anti-p-tyr). Stripping was complete, because control bands
containing HPK1 did not reappear on the 4G10-probed blot (data not
shown). Positions of important proteins are indicated on the
right. B, J14 cells were cotransfected with 10 µg each of plasmids encoding HA-tagged wild type (wt) or
Y379F mutant (YF) HPK1 and FLAG-tagged wild type
(wt) or SH2 mutant (RK) (37) SLP-76. Following
stimulation with medium ( ) or anti-CD3 and anti-CD4 antibodies for 3 min (+), cells were lysed and subjected to IP with polyclonal
anti-human SLP-76 antibodies. Input lysates representing 6.5 × 105 cells or precipitates representing 7 × 106 cells were analyzed via SDS-polyacrylamide gel
electrophoresis and immunoblotting. Shown are blots probed with
monoclonal antibodies against the HA ( -HA) or FLAG ( -FLAG) tags,
along with a Ponceau staining of a portion of a lysate blot as a
loading control.
|
|
We next investigated which regions of HPK1 and SLP-76 are required for
their interaction. J14 cells were cotransfected with cDNAs encoding
HA-tagged wild type or Y379F mutant HPK1 in combination with
FLAG-tagged wild type or SH2 R448K mutant SLP-76, which is incapable of
binding to tyrosine-phosphorylated ligands (37). As shown in Fig.
2B, immunoprecipitation of similar amounts of SLP-76
permitted significant co-precipitation of HA-HPK1 only in cells that
express wild type HA-HPK1 and wild type FLAG-SLP-76 (lanes
3 and 4). In all other cases, no significant
interaction was observed. The only slightly weaker interaction in
unstimulated cells (lane 3) may result from the
high expression levels of exogenous SLP-76 and HPK1 in combination with
significant levels of basal tyrosine kinase activity in these cells as
revealed by anti-phosphotyrosine probing of the lysate blots (data not
shown). Moreover, basal interactions between SLP-76 and HPK1 could be
mediated by Grb2/Gads or other adaptors. This notwithstanding, our
findings suggest that both Tyr379 of HPK1 and the SLP-76
SH2 domain are required for the HPK1/SLP-76 interaction in T cells,
which is augmented by TCR stimulation, particularly in the case of
endogenous proteins (Fig. 2A, lanes 3 and 4).
Full Activation of HPK1 in Response to TCR Stimulation Requires
Tyr379 of HPK1 and Intact Gads-binding and SH2 Domains of
SLP-76--
We have previously observed that full activation of HPK1
in response to antigen receptor stimulation is dependent on SLP-76 in T
cells and BLNK/SLP-65 in B cells (9). Our current finding, that HPK1 is
recruited into SLP adaptor complexes, provides a potential molecular
explanation for this observation. Therefore, we investigated the
dependence of HPK1 activation on its interaction with SLP-76. Using an
immune complex kinase assay, we measured the kinase activity of
HA-tagged wild type or Y379F mutant HPK1, following its transient
transfection into Jurkat cells. Our results show that activation of
HPK1 is significantly reduced by mutation of Tyr379 to
phenylalanine (Fig. 3A).
Notably, the low levels of HPK1 kinase activity remaining are
comparable with those observed in SLP-76-deficient J14 cells (Ref.
9 and Fig. 3B). These results support the idea that
activation of HPK1 depends on its interaction with the SLP-76 SH2
domain, mediated by phospho-Tyr379 of HPK1. To test this
model, we measured the dependence of HPK1 activation on the various
functional domains of SLP-76. Activation of wild type HPK1 was measured
in SLP-76-deficient J14 cells that were stably reconstituted with
vector or with constructs encoding wild type or mutant forms of SLP-76
(40). While vector-transfected cells only show an ~2-fold HPK1
activation in response to anti-TCR treatment, cells reconstituted with
wild type SLP-76 restored HPK1 activation to 6-fold above that of
unstimulated controls (Fig. 3B). In contrast, the SLP-76
mutant in which the Grb2/Gads binding region 224-244 was deleted
( Gads) failed to rescue HPK1 activation. In addition, the SLP-76
R448K mutant (SH2mut), which harbors a phosphotyrosine
binding-deficient SH2 domain (37), was unable to rescue HPK1
activation. Mutants in which residues 157-223 were deleted ( P-1) or
in which critical tyrosine residues required for effector interactions
with the SLP-76 N terminus were changed to phenylalanine (Y3F) (42)
both rescued HPK1 activation. These results suggest that binding of
HPK1 via phosphorylated Tyr379 to the SH2 domain of SLP-76
is required for its activation. In addition, our results demonstrate
that binding of Grb2 type adaptors to SLP-76 is required for full HPK1
activation.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 3.
Full HPK1 activation by the TCR requires
Tyr379 of HPK1 as well as the Gads-binding and SH2 domains
of SLP-76. A, Jurkat cells were transiently transfected
with HA-tagged wild type or Y379F mutant HPK1 to equal expression
levels (data not shown) and stimulated for 1 min with buffer or the
anti-TCR antibody C305. Cells were then lysed, and anti-HA
immunoprecipitates were assayed for HPK1 kinase activity. B,
SLP-76-deficient J14 cells stably reconstituted with vector, wild type
SLP-76, or one of the SLP-76 mutants P-1, Y3F, Gads, or
SH2mut, which harbors a phosphotyrosine binding-deficient
SH2 domain (37), were transfected with HA-tagged HPK1 and treated with
the anti-TCR antibody C305 or a buffer control for 1 min. HPK1
catalytic activity was measured as described above. In all experiments,
immunoprecipitates contained similar amounts of HPK1 protein as
determined by immunoblotting with anti-HA antibodies. A blot from one
representative experiment is shown in the bottom
panel. Cell surface expression of the TCR on all J14 lines
was comparable. In A and B, HPK1-activities are
shown as the mean -fold induction compared with unstimulated cells from
three independent experiments. Error bars
represent S.D.
|
|
The SH2 Domain of SLP-76 Participates in the Regulation of AP-1 and
NFAT Activation in Response to TCR Stimulation--
Previous studies
involving overexpression of SLP-76 in Jurkat cells (37) or expression
of LAT/SLP-76 chimeric proteins in LAT-deficient J.CaM2 cells (43) have
suggested a positive but nonessential role for the SLP-76 SH2 domain in
TCR-induced NFAT and IL-2 promoter activation. To further investigate
the role of the SLP-76 SH2 domain in the regulation of IL-2 promoter
elements, we examined TCR-induced activation of AP-1 and NFAT in
SLP-76-deficient J14 cells transiently transfected with either wild
type or R448K mutant SLP-76 to similar expression levels as judged on
immunoblots (Fig. 4). A weak background
band that migrates at the position of SLP-76 on blots of untransfected
(data not shown) or vector-transfected cells could represent a
nonspecific cross-reactivity of the anti-SLP-76 antibody or a very weak
residual expression of SLP-76 in J14 cells. However, anti-SLP-76
immunoprecipitation experiments argue against a significant expression
of SLP-76 in J14 cells (Fig. 2A and Ref. 13), and
compared with Jurkat cells, J14 cells are clearly impaired in
TCR-induced pIL-2, NFAT, and AP-1 activation, arguing against significant residual SLP-76 function (13). As expected, J14 cells
showed no significant AP-1 or NFAT activation in response to anti-TCR
stimulation with two different antibodies (C305 and UCHT1) in the
absence or presence of CD4/CD28 co-cross-linking (Fig. 4). Transfection
of wild type SLP-76 allowed efficient activation of both reporter
genes, which was maximal in the presence of costimulatory antibodies.
However, transfection of R448K mutant SLP-76 rescued AP-1 and NFAT
activation less efficiently, particularly in the absence of
costimulation. Experiments with two different NFAT reporter constructs
(either pGL-IL-2E, which contains three copies of the IL-2E element,
which binds NFAT and Ets-factors (Fig. 4) (39), or pNFAT-TA-Luc, which
contains three tandem copies of the NFAT consensus sequence upstream of
the minimal TA promoter (data not shown)) yielded similar results.
SLP-76 R448K consistently yielded lower activation levels of AP-1 than
wild type SLP-76 over a range of SLP-76 protein expression levels in
titration experiments (data not shown). Moreover, analyses of J14 cells stably reconstituted with various mutants of SLP-76 yielded similar results (40). However, the defect in NFAT activation in cells expressing the SH2 mutant is less severe than the defect seen when
other domains of SLP-76 were mutated. Reconstitution of LAT-deficient cells with various LAT/SLP-76 chimeras provided similar results (43).
Taken together, these results demonstrate that the SLP-76 SH2 domain
contributes to activation of both AP-1 and NFAT in response to TCR
stimulation but does not play an essential role.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 4.
The SLP-76 SH2 domain contributes to full
activation of AP-1 and NFAT in response to TCR stimulation.
SLP-76-deficient J14 cells were transiently cotransfected with 3 µg
of parental vector (pEF-BOS) or expression constructs containing wild
type (SLP-76 wt) or R448K mutant (SLP-76 RK)
SLP-76 cDNAs in addition to 2 µg of pCMV Gal
reporter plasmid and 20 µg of either AP-1 luciferase reporter plasmid
(AP1) (9, 77) or pGL-IL-2E reporter plasmid (NFAT) (39). Aliquots of
all samples containing equal cell numbers were lysed and subjected to
-galactosidase assays or immunoblot analysis for SLP-76 expression
(insets). wt, wild type; RK, R448K
mutant SLP-76; dash, vector-transfected cells. Equal loading
of lysates was verified by Ponceau staining of the blots prior to
probing (Pon). Following stimulation with medium
(Mock) or anti-TCR antibodies (C305 or UCHT1) or a mixture
of antibodies directed against CD3, CD4, and CD28 (CD3/4/28) or a
combination of PMA and Ionomycin (P/I), cells were lysed, and
luciferase activities were determined and normalized to
-galactosidase activities. All stimulation assays were performed in
triplicate. Shown are mean -fold stimulation values compared with
mock-stimulated cells. Error bars represent S.D.
values. Normalization to SLP-76 expression levels instead of
-galactosidase activities yielded essentially identical results
(data not shown), even if absolute activities were compared. Several
independent experiments yielded similar results, even if another
reporter construct was used for NFAT activation assays (data not
shown).
|
|
Stimulation downstream of SLP-76 via PMA/ionomycin elicited strong
responses even in untransfected (data not shown) and vector-transfected J14 cells (Fig. 4), indicating that the cells have no inherent signaling defect. Notably, we consistently observed a reproducible increase in PMA/ionomycin-induced AP-1 or NFAT activation with decreasing SLP-76 function; reporter gene activation was minimal (albeit high) in wild type SLP-76-transfected cells, intermediate in
cells expressing R448K mutant SLP-76, and maximal in vector transfected
J14 cells. Thus, in addition to being required for TCR-induced
activation of AP-1 and NFAT, SLP-76 may also be involved in the
transmission of inhibitory signals that limit activation of AP-1 and
NFAT via pathways downstream or independent of PLC-, RasGRP-, or
Ca2+-mediated events. The SLP-76 SH2 domain ligand SLAP-130
could possibly participate in such signals, since its overexpression had negative effects on NFAT/AP-1/pIL-2 activation under certain circumstances (16, 18). These possibilities require further investigation.
HPK1 Inhibits TCR-stimulated AP-1 Activation in a Manner Partially
Dependent on Tyr379 of HPK1 and an Intact SLP-76 SH2
Domain--
We recently demonstrated an inhibitory role for HPK1 in
TCR-induced AP-1 activation in Jurkat cells. This inhibition requires the kinase activity of HPK1 (9). Full activation of HPK1 in response to
TCR stimulation appears to require the physical interaction of HPK1
with the SLP-76 SH2 domain (Figs. 2 and 3). Therefore, we next
investigated the effects of mutations that abrogate or reduce this
interaction on TCR-induced AP-1 activation (Fig.
5). J14 cells were transiently
transfected with either wild type or R448K mutant SLP-76 to similar
expression levels (compare immunoblots in Fig. 5B) and
cotransfected with increasing amounts of wild type or Y379F mutant
HPK1. As shown in Fig. 5A, wild type HPK1 acts as a strong,
dose-dependent inhibitor of AP-1 activation in response to
CD3 stimulation in the absence and presence of costimulatory signals,
in cells expressing wild type or R448K mutant SLP-76. However, Y379F
mutant HPK1, expressed at levels similar to those of wild type HPK1,
inhibits AP-1 activation much less potently in cells expressing wild
type SLP-76. The difference in inhibition between wild type and Y379F
mutant HPK1 is maximal at low HPK1 expression levels but still
significant over the entire dose range except for maximal expression
levels, where almost complete inhibition of AP-1 activation is observed
and both curves converge. In striking contrast, no significant
difference in inhibitory potency between wild type and Y379F mutant
HPK1 is observed in cells that coexpress R448K mutant SLP-76. Thus,
Tyr379 of HPK1 is required for full inhibitory activity of
HPK1 on TCR-induced AP-1 activation, but only in the context of a
functional SLP-76 SH2 domain. This result suggests that
Tyr379 of HPK1 and the SLP-76 SH2 domain interact
functionally, and in view of our other results (Figs. 2 and 3), this
functional interaction is likely to reflect the molecular interaction
of HPK1 and SLP-76 via its SH2 domain and phosphorylated
Tyr379 of HPK1.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 5.
HPK1 inhibits TCR-induced AP-1 activation in
a manner partially dependent on its interaction with SLP-76.
A, J14 cells were transiently cotransfected with 3 µg of
PEF-BOS (J14), pEF/FLAG/SLP-76 wild type (wt-SLP-76), or
pEF/FLAG/SLP-76 R448K (RK-SLP-76), 2 µg of
pCMV Gal, 20 µg of AP-1 luciferase reporter plasmid
(AP1) (9, 77), and 0, 0.3, 1, 3, or 10 µg of plasmids encoding
HA-tagged wild type (wt-HPK1) or Y379F mutant
(YF-HPK1) HPK1. Total DNA levels were adjusted to 35 µg by
the addition of parental pEF-BOS DNA. Cells were subsequently
stimulated with medium (Mock), UCHT1 ( -CD3), a
combination of antibodies against CD3, CD4, and CD28 ( -CD3 + -CD4 + -CD28), or PMA/ionomycin (P/I) and assayed
as described in the legend to Fig. 4. All stimulation assays were
performed in triplicate. Shown are mean -fold stimulation values
compared with mock-stimulated cells. Error bars
represent S.D. values. B, aliquots of all samples containing
equal cell numbers were subjected to immunoblot analysis
(IB) for SLP-76 and HPK1-HA expression. Equal loading of
lysates was verified by Ponceau staining of the blots prior to probing
(Ponceau).
|
|
Definition of a Structural Motif Mediating HPK1 Binding to SLP
Family SH2 Domains--
The importance of Tyr379 in
HPK1/BLNK and HPK1/SLP-76 interactions prompted us to evaluate HPK1
sequence motifs in more detail. SLAP-130/FYB has been identified as a
phosphotyrosine-dependent ligand for the SLP-76 SH2 domain
(16, 17, 20, 21). We therefore compared the amino acid sequences of
human (h) and murine (m) HPK1 and SLAP-130 in the region of HPK1
surrounding Tyr379(m)/381(h) and in four related regions
(labeled a-d) in SLAP-130 (Fig.
6A). Regions b
(Tyr595) and c (Tyr651) of human SLAP-130 have
recently been implicated in binding to the SLP-76 SH2 domain upon
phosphorylation of SLAP-130 by Fyn-T (20, 21). All of the compared
regions contain a tyrosine (Tyr0) flanked by acidic
residues at positions 6 (corresponding to 5 in mHPK1, which carries
a one-amino acid deletion N-terminal of 3), 2, +1, and +2. At
position +3, a hydrophobic residue is strictly conserved. Some features
are only shared by HPK1 and subsets of the SLAP-130 fragments. These
include acidic residues at positions 3, +4, +27, and +28. Based on
these sequence similarities, we defined a candidate consensus motif for
BLNK/SLP-76 SH2 domain ligands (Fig. 6A,
bottom).

View larger version (59K):
[in this window]
[in a new window]
|
Fig. 6.
HPK1 and SLAP-130 share a candidate ligand
motif for SLP adaptor SH2 domains. A, manual alignment
of regions from published human HPK1 (U66464), SLAP-130 (U93049,
regions a-d), SKAP55 (Y11215), SKAP55R (AJ004886), Vav
(p15498), Vav-2 (s76992), and Vav-3 (AF118887) sequences. Positions
within the respective full-length sequences are indicated on the
right. The box indicates the region that fits
into the ligand binding surface of SLP adaptor SH2 domains (compare
Fig. 7C). Homologous residues shared between HPK1 and
SLAP-130 regions are highlighted. All regions contain a Tyr
(Y0, boldface type) in an
acidic sequence context. In addition, a hydrophobic amino acid at
position +3 is conserved. A putative consensus motif shared between
HPK1 and SLAP130c or all fragments (allow degeneracy for the positions
labeled with an asterisk) is depicted below the
alignment. A second match to the consensus in SKAP55R is
underlined. Several regions also contain a candidate target
motif for cleavage by caspases (DDXD) (78) immediately
following Tyr0. Additional physicochemical features shared
between HPK1 and several SLAP-130 fragments include a proline-rich
region C-terminal of the candidate target region and acidic residues at
positions +27/+28. Identical results were found for the available
murine relatives of the proteins shown here. B, schematic
depiction of the positions of the candidate SLP adaptor SH2 domain
target sites (Y) shown in A within the respective
full-length proteins. SKAP55 and Vav represent the corresponding gene
families. Domains are labeled as in Fig. 1. PPP,
proline-rich domain; NLS, nuclear localization sequence. In
Vav, the candidate target site is located within the acidic
region.
|
|
Although we screened yeast clones at ~86-fold redundancy of the
library, our analysis did not identify all known BLNK interactors. Both
Vav and HPK1 clones were highly underrepresented relative to Gads. No
SLAP-130 homolog was found. We therefore searched protein data bases
and GenBankTM for genes that are related to our consensus
motif or to SLAP-130 and that might therefore represent novel BLNK or
SLP-76 SH2 domain interactors. PATTERNFIND, PHI-BLAST, and manual
searches identified both SLAP-130 and HPK1, but the BLNK/SLP-76
consensus motif was also found in additional proteins, including
the SKAP55 and Vav families (Fig. 6, A and
B).
Sequence comparisons by themselves do not suggest identical ligand
specificities for SLP-76, BLNK, and CLNK/MIST, a recently identified third SLP family member (Data not shown; see Refs. 44 and
45). We therefore analyzed the structural features of their SH2
domains. Compared with published SH2 domain alignments (46), SLP family
SH2 domains are characterized by extended BC, FB, and BG loops (Fig.
7, A and B). Loops
AB and CD carry deletions. Most of the residues frequently involved in
ligand interactions are conserved between all SLP family members, with
the exceptions of D6, E4, B9, BG3, and BG4 (Fig.
7A) (46, 47). A three-dimensional representation, in which
the aligned hBLNK SH2 domain sequence was modeled based on the crystal
structure of the SH2 domain of full-length Src complexed to the Src C
terminus (38), illustrates that the ligand binding groove accommodates
a tyrosine-phosphorylated hHPK1 undecapeptide including residues 4 to
+6 flanking the phosphotyrosine (Fig. 7B). Similar results
were obtained for all known SLP family SH2 domains binding to
tyrosine-phosphorylated HPK1 or SLAP-130c ligand peptides. An enlarged
view in which SH2 domain amino acids within a 4-Å distance from the
ligand peptide are superimposed for hBLNK, mCLNK, and hSLP-76 reveals
that most residues that can interact with the phosphopeptide ligand are
homologous (Fig. 7, A and C). The phosphotyrosine
appears embedded in a pocket in which basic side chains ( A2, B5)
participate in phosphate binding. Asp+1 extends
inward, likely interacting with the basic side chains of BG4 and the
backbone carbonyl of D4, in addition to a nonpolar interaction with
D5 and a possible -interaction with the aromatic ring of the
conserved tyrosine D3. Asp+2 extends away from the SH2
domain surface toward the solvent. Val+3 is embedded in a
pocket and might be involved in hydrophobic interactions with the
conserved LEF1 and stabilizing backbone interactions with
BG4. In addition, Asp+4 could undergo polar interactions
with EF3, and Asp 3 could interact weakly with A3 in
hBLNK and mCLNK. Other positions including +2 do not appear to
participate in specificity determination. These observations are
consistent with the definition of our consensus motif and suggest that
HPK1 and SLAP-130 a and c (Fig. 6A), along with SKAP55 and
Vav family proteins, could be optimal ligands. SLAP-130 c
(Tyr651) has indeed recently been implicated in
Fyn-T-mediated binding to the SLP-76 SH2 domain (20, 21). A region of
SLAP-130 (RTARGSY559GYIKTTAV) that does not match our
consensus has recently been identified as another SLP-76 SH2 domain
ligand (18). Modeling analyses suggest that this peptide can be
accommodated, but the interaction is predicted to be much weaker than
with peptides that harbor the consensus motif (data not shown).

View larger version (78K):
[in this window]
[in a new window]
|
Fig. 7.
Structure models support binding of our
ligand consensus motif to SLP adaptor SH2 domains. A,
sequence alignment of the SH2 domains of Src and representative SLP
family members. Secondary structure elements are labeled as in Ref. 46.
Boxes indicate -helices ( ) and -sheets ( ) that
are structurally conserved between all SH2 domains. Residues important
for ligand binding in many SH2 domains are denoted above the
blocks. Amino acids within a 4-Å distance from modeled
ligand peptides are highlighted. B, overlay of the crystal
structure of the human Src SH2 domain bound to the Src C terminus
(purple, taken from the full-length human Src crystal
structure) (38) with the modeled structure of the hBLNK SH2 domain
(yellow). The hHPK1-(377-387) ligand peptide was
modeled into the corresponding orientation of the C-terminal Src
peptide. HPK1 residues are color-coded by atom type (green,
carbon; red, oxygen; blue, nitrogen;
purple, phosphor). N and C termini and -helices
( A/ B) of the SH2 domains are indicated. AB,
BC, BG, CD, and FB, loops
showing major structural changes. pY, phosphorylated
Tyr381 of hHPK1. Flanking residues are numbered ( ,
N-terminal neighbors; +, C-terminal neighbors). C, model
showing SH2 domain residues within a 4-Å distance from the hHPK1
ligand peptide. For comparison, corresponding amino acids in the SH2
domains of hBLNK, hSLP-76, and mCLNK were overlaid. SH2 domain residue
color coding is as follows: blue, basic; green,
polar; yellow, sulfur-containing; purple,
nonpolar. HPK1 peptide color coding is as in B, except that
C is yellow.
|
|
 |
DISCUSSION |
Identification of Novel BLNK Interaction Partners--
We isolated
fragments of Vav, Gads, and HPK1 as BLNK interactors in a Syk-driven
yeast two-hybrid screen. The isolation of Vav as a partially
Syk-dependent interactor in yeast corroborates previous
reports that Vav shows a basal interaction with SLP-76 and BLNK, which
is enhanced by antigen receptor stimulation and involves the Vav SH2
domain (22, 23, 48, 49). The identification of Gads as a
phosphotyrosine-independent interaction partner for BLNK is reminiscent
of the SH3-dependent interactions of Grb2 with BLNK (22,
23) or Grb2 and Gads with SLP-76 (3, 4, 6). Gads has recently been
found to be expressed in certain B cell subsets including naive
tonsillar B cells and associates with BLNK in MP-1 cells (50).
HPK1 Is a Phosphotyrosine-dependent Interactor for SLP
Adaptor SH2 Domains--
We identified HPK1 (35, 36) as a strictly
phosphotyrosine-dependent BLNK interactor. Two-hybrid
analyses demonstrate that this interaction is mediated by
phosphorylation of HPK1 on Tyr379 and its binding to the
BLNK SH2 domain (Fig. 1C). These results are confirmed and
complemented by findings of Tsuji et al. (81), of
which we learned while our studies were in progress. This group isolated HPK1 as a protein that associates with the BLNK SH2 domain in
lysates of BCR-stimulated B cells. The interaction depends on
Tyr379 of HPK1 and an intact BLNK SH2 domain in
cotransfected mammalian cells. The authors also demonstrate that BCR
stimulation induces tyrosine phosphorylation of HPK1 in B cell lines in
a manner mainly dependent on Syk and Lyn. Full activation of HPK1
requires both Tyr379 and an intact BLNK SH2 domain
(81).
We demonstrate the occurrence and functional significance of a similar
interaction of HPK1 with SLP-76 in T cells. HPK1 associates with SLP-76
and a tyrosine-phosphorylated protein most likely representing LAT in
anti-TCR stimulated Jurkat cells (Fig. 2A). In cotransfected
J14-cells (Fig. 2B), the HPK1/SLP-76 interaction requires
Tyr379 of HPK1 and the SLP-76 SH2 domain, both of which are
also required for full activation of HPK1 in response to TCR
stimulation (Fig. 3). Finally, we show that the SLP-76 SH2 domain
contributes to full AP-1 and NFAT activation in response to TCR
stimulation (Fig. 4) and that HPK1 inhibits AP-1 activation in a manner
partially dependent on Tyr379 of HPK1 and the SLP-76 SH2
domain (Fig. 5). Importantly, the dependence on Tyr379 of
HPK1 is relieved by concomitant mutation of the SLP-76 SH2 domain. This
provides genetic evidence for a functional interaction between HPK1 and
SLP-76 that involves these complementary interaction domains.
Associations of the SLP-76 SH2 domain with a tyrosine-phosphorylated
protein and a putative serine/threonine kinase, both of ~100 kDa, in
anti-TCR-stimulated Jurkat cells have been reported previously (37).
Moreover, an association of Gads with BLNK and an unknown
serine/threonine kinase activity, which was increased after BCR
stimulation, has recently been found in B cells (50). Our results
suggest that these activities represent HPK1, a 97-kDa protein.
Complementing our detection of possibly tyrosine-phosphorylated HPK1 in
SLP-76 immunoprecipitates from anti-TCR-stimulated Jurkat cells (Fig.
2A), TCR stimulation has recently been shown to induce tyrosine phosphorylation of a small fraction of HPK1 in murine DO11.10
T hybridoma cells and Jurkat cells (10, 11).
Based on homology models, we defined a structural motif that mediates
ligand binding to SLP adaptor SH2 domains (Fig. 6A). Both
Src- and Syk-type PTKs show strong preferences for substrate tyrosine
residues (Tyr0) in an acidic sequence context. However,
while Syk family PTKs strongly prefer acidic residues as immediate
neighbors of Tyr0 (51, 52), Src-type PTKs favor hydrophobic
amino acids at position 1 (52-55). Thus, HPK1 Tyr379/381
should be a perfect substrate for Syk kinases, while the tyrosines in
SLAP-130 b-d should be preferred substrates for Src-PTKs. This could
explain why we isolated HPK1 as a Syk-dependent BLNK
interactor, whereas SLAP-130 was in part isolated as a
Fyn-dependent SLP-76 interactor (16, 17, 20, 21). The
affinities between SH2 domains and their ligands are mainly determined
by interactions with the phosphorylated Tyr0 and the 3-6
residues C-terminal of it. Positions +1, +2, and +3 generally appear
most critical (7, 46, 47). Our structural modeling analyses suggest
that all SLP adaptor SH2 domains show strong preferences for acidic
amino acids at +1 and hydrophobic residues at +3. Acidic side chains at
3 and +4 may increase ligand affinity, particularly for BLNK (Fig.
7C). Precedents for participation of positions +4 or +5 or
of residues N-terminal of Tyr0 do exist (46, 56-59). The
similarity between the SLP family SH2 domain target motif and that of
Src-type SH2 domains (YXXL in an acidic context, where
X is preferably acidic) (46, 56), suggests that HPK1 and
SLAP-130 can bind to both. Indeed, SLAP-130 has been shown to interact
with the SH2 domain of Fyn (14). Finally, our data base searches
revealed that the Vav and SKAP55 families have a structural propensity
for SLP adaptor SH2 domain interactions (Fig. 6A). While
SKAP55 adaptors associate with SLAP-130 via SH3 domain interactions
(60, 61), Vav can bind to tyrosine-phosphorylated SLP adaptors via its
SH2 domain (3, 6, 22, 26, 27). Thus, HPK1, SLAP-130, SKAP55 adaptors,
and Vav have all been described in SLP adaptor assemblies and almost
certainly participate in complex, possibly competitive, interactions
with SLP adaptor SH2 domains.
A Model for Antigen Receptor-stimulated Activation of
HPK1--
HPK1 has only recently been implicated in signal
transduction from antigen receptors (9-12). Engagement of TCR or BCR
results in activation of HPK1. This activation was abrogated in T cells lacking Lck, ZAP-70, or LAT or in B cells lacking Lyn and Syk or
lacking Grb2 and Grap (9). In T cells, HPK1 associates via its
proline-rich domains P2 and P4 (Fig. 1B) with the SH3
domains of Grb2 adaptors (10-12, 62). These interactions and the Gads SH2 domain are required for maximal tyrosine phosphorylation of HPK1
(10, 62). These results are consistent with a model in which activation
of antigen receptors results in the recruitment of HPK1 to
membrane-bound, tyrosine-phosphorylated linker proteins (LAT in T
cells) via its constitutive interaction with Grb2 family members (Fig.
8). In T cells, TCR stimulation induces
the parallel recruitment of SLP-76 to LAT via Gads, with which it
associates constitutively via SH3 domain interactions (3, 4, 6). Our
co-precipitation data support the recruitment of LAT, SLP-76, and HPK1
into a molecular complex (Fig. 2). Upon relocation into antigen
receptor complexes, HPK1 is phosphorylated on Tyr379,
presumably by Syk family PTKs. This allows HPK1 to interact with the
SH2 domains of SLP adaptors. These interactions appear essential for
full activation of HPK1, because HPK1 activation is strongly reduced in
SLP-76-deficient T cells or BLNK-deficient B cells (Fig. 3B
and Ref. 9). In addition, full activation of HPK1 in response to
TCR stimulation requires Tyr379 plus the Gads-binding and
SH2 domains of SLP-76 (Fig. 3). Since Tyr379 is immediately
adjacent to proline-rich region P2 of HPK1 (Fig. 1B), SLP
adaptor binding could abrogate or modify P2-dependent Grb2
adaptor interactions (10, 12). This might modulate HPK1 activity or
substrate access, with concomitant effects on downstream signaling
events.

View larger version (50K):
[in this window]
[in a new window]
|
Fig. 8.
A model for TCR-induced membrane recruitment
and activation of HPK1. TCR stimulation leads to activation of
TCR-proximal Src family (Lck, Fyn) and ZAP-70 family (ZAP-70, Syk)
PTKs. PTK-mediated phosphorylation of the transmembrane adaptor protein
LAT permits Grb2/Gads-dependent membrane recruitment of
SLP-76 and HPK1. While this may lead to partial activation of HPK1,
full activation of HPK1 requires its own tyrosine phosphorylation, most
likely by ZAP-70/Syk, and its subsequent binding to the SLP-76 SH2
domain. This may occur in parallel or antagonistically to interactions
of tyrosine-phosphorylated SLAP-130 with the SLP-76 SH2 domain. HPK1
negatively regulates Erk and AP-1 activation (Ref. 9 and this study).
In addition, HPK1 may connect antigen receptors to activation of the
JNK and IKK cascades (9, 12, 75, 79-81). For further
explanations, see "Discussion."
|
|
A Role for HPK1 in Signal Transduction via SLP-76 in T Cells and
BLNK in B Cells--
Previous studies suggested a positive, but
nonessential, role for the SLP-76 SH2 domain in the TCR-induced
activation of NFAT and pIL-2 (37, 43). The results of our
cotransfection experiments in SLP-76-deficient J14 cells extend this
observation and suggest that the SLP-76 SH2 domain contributes to full
activation of both AP-1 and NFAT in response to TCR stimulation (Figs.
4 and 5). Studies with stably reconstituted J14 cells yielded similar
results but demonstrate that the SH2 domain is less important than
other regions of SLP-76 (40). We recently demonstrated that HPK1 acts as a negative regulator of TCR-induced Erk and AP-1 activation and that
the inhibitory function of HPK1 requires its kinase activity (9). Here
we confirm this finding and show that the interaction of HPK1 with the
SLP-76 SH2 domain is required for activation of HPK1 (Fig. 3) and
facilitates inhibition of AP-1 activation by HPK1 (Fig. 5). Thus, the
SLP-76 SH2 domain is involved in both positive (AP-1/NFAT activation
via as yet unknown pathways) and negative (inhibition of AP-1
activation via HPK1) branches of TCR signaling. This may explain why
SLP-76 SH2 domain mutants so far showed only modest phenotypes (this
study and Refs. 37, 40, and 43) and why the function of SLAP-130 is
still unclear (16-21, 63).
HPK1 could in principle inhibit AP-1 activation by antagonizing the
recruitment of positive effectors to the SLP-76 SH2 domain. A positive
role for SLAP-130 in TCR-stimulated pIL-2 and NFAT activation has been
suggested (17, 19-21, 63). Thus, it will be interesting to address
experimentally a potential antagonism of HPK1 on SLAP-130 signaling.
However, HPK1 still inhibits activation of AP-1 (Fig. 5) and NFAT (data
not shown) in the presence of mutations that abrogate the SLP-76
interaction, albeit less efficiently. One possible explanation could be
competition of HPK1 with positive effectors for binding to other
components of the TCR complex (e.g. Grb2 family adaptors).
Experiments with a kinase-inactive mutant of HPK1 suggest that the
kinase activity is required for its inhibitory effect on Erk, AP-1, and
NFAT activation (Ref. 9 and data not shown). Thus, the mechanism by
which HPK1 inhibits TCR signaling appears to include the
HPK1-dependent phosphorylation of signaling proteins. This
could provide an alternative explanation for the requirement for the
HPK1/SLP-76 SH2 domain interaction for full inhibitory activity of
HPK1, because this interaction is required for full activation of HPK1.
The residual, weaker inhibitory activity of HPK1 in the absence of
SLP-76 binding (Fig. 5) could be explained by additional,
SLP-76-independent mechanisms of HPK1 activation in T cells, possibly
mediated by interactions with other adaptors, including Nck or the Grb2
or Crk families (10-12, 62). Since HPK1 fails to inhibit AP-1
activation in cells treated with PMA alone (9) or in combination with
ionomycin (Fig. 5 and data not shown), it is likely to act upstream of
PKC and Ras activation. Thus, it will be interesting to investigate if
HPK1 regulates the activity of proximal components of the TCR complex
via their phosphorylation. Possible candidates are components of the
Erk pathway, particularly PLC , RasGRP, and Sos. A negative
regulation of Sos via phosphorylation by serine/threonine kinases has
been reported (64-68), although the situation may be more complex in lymphocytes (69, 70).
Multiple studies have implicated HPK1 as a potent activator of the JNK
cascade (see Refs. 35, 36, and 71 and references within Refs. 72 and
73). Therefore, HPK1 may provide a novel link between SLP adaptors and
the JNK pathway. However, the role of HPK1 in JNK regulation in T cells
is still unclear (9, 12). A likely explanation is the involvement of
costimulatory signals in JNK activation (74). In one study, HPK1 has
recently been implicated in a signaling cascade that activates JNK in
response to TCR/CD28-costimulation in Vav-transfected Jurkat cells
(75). Gene disruption studies have shown that BLNK is required for
BCR-induced activation of the JNK cascade via as yet incompletely
understood mechanisms (28). A participation of HPK1 in JNK regulation
in B cells has not been demonstrated, but it represents a testable hypothesis that can be addressed by interfering with HPK1 function in
lymphocytes. Apart from gene disruptions, transgenic overexpression of
dominant negative HPK1 mutants, which disrupt functional interactions of endogenous proteins, in developing lymphocytes in mice provides a
powerful approach to analyze functions of HPK1 in lymphocyte signaling
in a physiological context, even in a situation of potential functional
redundancies with other STE-20-related protein kinases.
 |
ACKNOWLEDGEMENTS |
We thank Jenny Tian, Hai-Zhuan Zhang, Erin
Armstead, and Theresa Kadlecek for technical assistance; Ed O'Neill,
Satoshi Takaki, Ed Clark, Gary Koretzky, and Friedemann Kiefer for
reagents; Julie deMartino, Petra Doerfler, Friedemann Kiefer, Daisuke
Kitamura, Marty Springer, and Xiaoming Zou for critical comments on the manuscript; and current and past members of the Perlmutter and Weiss
laboratories for many stimulating discussions.
 |
Note Added in Proof |
An interaction of HPK1 with CLNK has
recently been reported in Yu et al. (Yu, J., Riou, C.,
Davidson, D., Minhas, R., Robson, J. D., Julius, M., Arnold, R.,
Kiefer, F., and Veillette, A. (2001) Mol. Cell. Biol.
21, 6102-6112).
 |
FOOTNOTES |
*
This work was supported in part by NCI, National Institutes
of Health, Grant RO1 CA72531 (to A. W.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom all correspondence should be addressed. Tel.:
732-594-4045; Fax: 732-594-5140; E-mail: Karsten_Sauer@Merck.com.
¶
These two authors contributed equally to this work.
§§
An investigator of the Howard Hughes Medical Institute.
¶¶
Present address: Amgen Inc., 1 Amgen Center Dr.,
Thousand Oaks, CA 91320.
Published, JBC Papers in Press, August 3, 2001, DOI 10.1074/jbc.M106811200
 |
ABBREVIATIONS |
The abbreviations used are:
PTK, protein-tyrosine kinase;
BCR, B cell receptor;
BLNK, B cell linker
protein;
hBLNK, human BLNK;
HPK1, hematopoietic progenitor kinase 1;
mHPK1, murine HPK1;
LAT, linker for activation of T cells;
PI3K, phosphatidylinositol 3-kinase;
PLC, phospholipase C;
PTB, phosphotyrosine binding domain;
SH2 and SH3, Src homology 2 and 3 domain, respectively;
SLAP-130, SLP-76-associated phosphoprotein of 130 kD;
SLP-76, Src homology 2 domain-containing leukocyte phosphoprotein
of 76 kDa;
JNK, c-Jun N-terminal kinase;
PCR, polymerase chain
reaction;
X-gal, 5-bromo-4-chloro-3-indolyl
-D-galactopyranoside;
IL, interleukin;
PMA, phorbol
12-myristate 13-acetate;
TCR, T cell receptor;
CLNK, cytokine-dependent
hemopoietic cell linker;
MIST, mast cell immunoreceptor signal
transducer.
 |
REFERENCES |
| 1.
|
Campbell, K. S.
(1999)
Curr. Opin. Immunol.
11,
256-264
|
| 2.
|
Huber, M.
(2000)
EMBO Rep.
1,
308-312
|
| 3.
|
Norian, L. A.,
and Koretzky, G. A.
(2000)
Semin. Immunol.
12,
43-54
|
| 4.
|
Zhang, W.,
and Samelson, L. E.
(2000)
Semin. Immunol.
12,
35-41
|
| 5.
|
Kane, L. P.,
Lin, J.,
and Weiss, A.
(2000)
Curr. Opin. Immunol.
12,
242-249
|
| 6.
|
Myung, P. S.,
Boerth, N. J.,
and Koretzky, G. A.
(2000)
Curr. Opin. Immunol.
12,
256-266
|
| 7.
|
Pawson, T.,
and Nash, P.
(2000)
Genes Dev.
14,
1027-1047
|
| 8.
|
Janes, P. W.,
Ley, S. C.,
Magee, A. I.,
and Kabouridis, P. S.
(2000)
Semin. Immunol.
12,
23-34
|
| 9.
|
Liou, J.,
Kiefer, F.,
Dang, A.,
Hashimoto, A.,
Cobb, M. H.,
Kurosaki, T.,
and Weiss, A.
(2000)
Immunity
12,
399-408
|
| 10.
|
Liu, S. K.,
Smith, C. A.,
Arnold, R.,
Kiefer, F.,
and McGlade, C. J.
(2000)
J. Immunol.
165,
1417-1426
|
| 11.
|
Ling, P.,
Meyer, C. F.,
Redmond, L. P.,
Shui, J.-W.,
Davis, B.,
Rich, R. R.,
Hu, M. C.-T.,
Wange, R. L.,
and Tan, T.-H.
(2001)
J. Biol. Chem.
276,
18908-18914
|
| 12.
|
Ma, W.,
Xia, C.,
Ling, P.,
Qiu, M.,
Luo, Y.,
Tan, T. H.,
and Liu, M.
(2001)
Oncogene
20,
1703-1714
|
| 13.
|
Yablonski, D.,
Kuhne, M. R.,
Kadlecek, T.,
and Weiss, A.
(1998)
Science
281,
413-416
|
| 14.
|
Clements, J. L.,
Yang, B.,
Ross-Barta, S. E.,
Eliason, S. L.,
Hrstka, R. F.,
Williamson, R. A.,
and Koretzky, G. A.
(1998)
Science
281,
416-419
|
| 15.
|
Pivniouk, V.,
Tsitsikov, E.,
Swinton, P.,
Rathbun, G.,
Alt, F. W.,
and Geha, R. S.
(1998)
Cell
94,
229-238
|
| 16.
|
Musci, M. A.,
Hendricks-Taylor, L. R.,
Motto, D. G.,
Paskind, M.,
Kamens, J.,
Turck, C. W.,
and Koretzky, G. A.
(1997)
J. Biol. Chem.
272,
11674-11677
|
| 17.
|
da Silva, A. J.,
Li, Z.,
de Vera, C.,
Canto, E.,
Findell, P.,
and Rudd, C. E.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
7493-7498
|
| 18.
|
Boerth, N. J.,
Judd, B. A.,
and Koretzky, G. A.
(2000)
J. Biol. Chem.
275,
5143-5152
|
| 19.
|
Veale, M.,
Raab, M.,
Li, Z.,
da Silva, A. J.,
Kraeft, S. K.,
Weremowicz, S.,
Morton, C. C.,
and Rudd, C. E.
(1999)
J. Biol. Chem.
274,
28427-28435
|
| 20.
|
Geng, L.,
Raab, M.,
and Rudd, C. E.
(1999)
J. Immunol.
163,
5753-5757
|
| 21.
|
Raab, M.,
Kang, H.,
da Silva, A.,
Zhu, X.,
and Rudd, C. E.
(1999)
J. Biol. Chem.
274,
21170-21179
|
| 22.
|
Fu, C.,
Turck, C. W.,
Kurosaki, T.,
and Chan, A. C.
(1998)
Immunity
9,
93-103
|
| 23.
|
Wienands, J.,
Schweikert, J.,
Wollscheid, B.,
Jumaa, H.,
Nielsen, P. J.,
and Reth, M.
(1998)
J. Exp. Med.
188,
791-795
|
| 24.
|
Goitsuka, R.,
Fujimura, Y.,
Mamada, H.,
Umeda, A.,
Morimura, T.,
Uetsuka, K.,
Doi, K.,
Tsuji, S.,
and Kitamura, D.
(1998)
J. Immunol.
161,
5804-5808
|
| 25.
|
Ishiai, M.,
Kurosaki, M.,
Inabe, K.,
Chan, A. C.,
Sugamura, K.,
and Kurosaki, T.
(2000)
J. Exp. Med.
192,
847-856
|
| 26.
|
Kurosaki, T.,
and Tsukada, S.
(2000)
Immunity
12,
1-5
|
| 27.
|
Fruman, D. A.,
Satterthwaite, A. B.,
and Witte, O. N.
(2000)
Immunity
13,
1-3
|
| 28.
|
Ishiai, M.,
Kurosaki, M.,
Pappu, R.,
Okawa, K.,
Ronko, I.,
Fu, C.,
Shibata, M.,
Iwamatsu, A.,
Chan, A. C.,
and Kurosaki, T.
(1999)
Immunity
10,
117-125
|
| 29.
|
Jumaa, H.,
Wollscheid, B.,
Mitterer, M.,
Wienands, J.,
Reth, M.,
and Nielsen, P. J.
(1999)
Immunity
11,
547-554
|
| 30.
|
Minegishi, Y.,
Rohrer, J.,
Coustan-Smith, E.,
Lederman, H. M.,
Pappu, R.,
Campana, D.,
Chan, A. C.,
and Conley, M. E.
(1999)
Science
286,
1954-1957
|
| 31.
|
Pappu, R.,
Cheng, A. M.,
Li, B.,
Gong, Q.,
Chiu, C.,
Griffin, N.,
White, M.,
Sleckman, B. P.,
and Chan, A. C.
(1999)
Science
286,
1949-1954
|
| 32.
|
Hayashi, K.,
Nittono, R.,
Okamoto, N.,
Tsuji, S.,
Hara, Y.,
Goitsuka, R.,
and Kitamura, D.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
2755-2760
|
| 33.
|
Xu, S.,
Tan, J. E.,
Wong, E. P.,
Manickam, A.,
Ponniah, S.,
and Lam, K. P.
(2000)
Int. Immunol.
12,
397-404
|
| 34.
|
Yasuda, T.,
Maeda, A.,
Kurosaki, M.,
Tezuka, T.,
Hironaka, K.,
Yamamoto, T.,
and Kurosaki, T.
(2000)
J. Exp. Med.
191,
641-650
|
| 35.
|
Kiefer, F.,
Tibbles, L. A.,
Anafi, M.,
Janssen, A.,
Zanke, B. W.,
Lassam, N.,
Pawson, T.,
Woodgett, J. R.,
and Iscove, N. N.
(1996)
EMBO J.
15,
7013-7025
|
| 36.
|
Hu, M. C.,
Qiu, W. R.,
Wang, X.,
Meyer, C. F.,
and Tan, T. H.
(1996)
Genes Dev.
10,
2251-2264
|
| 37.
|
Motto, D. G.,
Ross, S. E.,
Wu, J.,
Hendricks-Taylor, L. R.,
and Koretzky, G. A.
(1996)
J. Exp. Med.
183,
1937-1943
|
| 38.
|
Xu, W.,
Doshi, A.,
Lei, M.,
Eck, M. J.,
and Harrison, S. C.
(1999)
Mol. Cell
3,
629-638
|
| 39.
|
Frantz, B.,
Nordby, E. C.,
Bren, G.,
Steffan, N.,
Paya, C. V.,
Kincaid, R. L.,
Tocci, M. J.,
O'Keefe, S. J.,
and O'Neill, E. A.
(1994)
EMBO J.
13,
861-870
|
| 40.
|
Yablonski, D.,
Kadlecek, T.,
and Weiss, A.
(2001)
Mol. Cell. Biol.
21,
4208-4218
|
| 41.
|
Bustelo, X. R.
(2000)
Mol. Cell. Biol.
20,
1461-1477
|
| 42.
|
Fang, N.,
Motto, D. G.,
Ross, S. E.,
and Koretzky, G. A.
(1996)
J. Immunol.
157,
3769-3773
|
| 43.
|
Boerth, N. J.,
Sadler, J. J.,
Bauer, D. E.,
Clements, J. L.,
Gheith, S. M.,
and Koretzky, G. A.
(2000)
J. Exp. Med.
192,
1047-1058
|
| 44.
|
Cao, M. Y.,
Davidson, D., Yu, J.,
Latour, S.,
and Veillette, A.
(1999)
J. Exp. Med.
190,
1527-1534
|
| 45.
|
Goitsuka, R.,
Kanazashi, H.,
Sasanuma, H.,
Fujimura, Y.,
Hidaka, Y.,
Tatsuno, A.,
Ra, C.,
Hayashi, K.,
and Kitamura, D.
(2000)
Int. Immunol.
12,
573-580
|
| 46.
|
Kuriyan, J.,
and Cowburn, D.
(1997)
Annu. Rev. Biophys. Biomol. Struct.
26,
259-288
|
| 47.
|
Songyang, Z.
(1999)
Prog. Biophys. Mol. Biol.
71,
359-372
|
| 48.
|
Wu, J.,
Motto, D. G.,
Koretzky, G. A.,
and Weiss, A.
(1996)
Immunity
4,
593-602
|
| 49.
|
Onodera, H.,
Motto, D. G.,
Koretzky, G. A.,
and Rothstein, D. M.
(1996)
J. Biol. Chem.
271,
22225-22230
|
| 50.
|
Yankee, T. M.,
Draves, K. E.,
Solow, S. A.,
Yun, T. J.,
Lau, F.,
Marshall, A. J.,
Ewings, M. K.,
and Clark, E. A.
(2000)
FASEB J.
14,
A966 (abstr.)
|
| 51.
|
Brunati, A. M.,
Donella-Deana, A.,
Ruzzene, M.,
Marin, O.,
and Pinna, L. A.
(1995)
FEBS Lett.
367,
149-152
|
| 52.
|
Schmitz, R.,
Baumann, G.,
and Gram, H.
(1996)
J. Mol. Biol.
260,
664-677
|
| 53.
|
Tinker, D. A.,
Cartron, J. L.,
McMurray, J. S.,
and Levin, V. A.
(1992)
Anticancer Res.
12,
123-127
|
| 54.
|
Songyang, Z.,
Carraway, K. L., III,
Eck, M. J.,
Harrison, S. C.,
Feldman, R. A.,
Mohammadi, M.,
Schlessinger, J.,
Hubbard, S. R.,
Smith, A. P.,
Eng, C.,
Lorenzo, M. J.,
Ponder, B. A. J.,
Mayer, B. J.,
and Cantley, L. C.
(1995)
Nature
373,
536-539
|
| 55.
|
Dente, L.,
Vetriani, C.,
Zucconi, A.,
Pelicci, G.,
Lanfrancone, L.,
Pelicci, P. G.,
and Cesareni, G.
(1997)
J. Mol. Biol.
269,
694-703
|
| 56.
|
Muller, K.,
Gombert, F. O.,
Manning, U.,
Grossmuller, F.,
Graff, P.,
Zaegel, H.,
Zuber, J. F.,
Freuler, F.,
Tschopp, C.,
and Baumann, G.
(1996)
J. Biol. Chem.
271,
16500-16505
|
| 57.
|
Meng, W.,
Sawasdikosol, S.,
Burakoff, S. J.,
and Eck, M. J.
(1999)
Nature
398,
84-90
|
| 58.
|
Li, S. C.,
Gish, G.,
Yang, D.,
Coffey, A. J.,
Forman-Kay, J. D.,
Ernberg, I.,
Kay, L. E.,
and Pawson, T.
(1999)
Curr. Biol.
9,
1355-1362
|
| 59.
|
Poy, F.,
Yaffe, M. B.,
Sayos, J.,
Saxena, K.,
Morra, M.,
Sumegi, J.,
Cantley, L. C.,
Terhorst, C.,
and Eck, M. J.
(1999)
Mol. Cell
4,
555-561
|
| 60.
|
Marie-Cardine, A.,
Hendricks-Taylor, L. R.,
Boerth, N. J.,
Zhao, H.,
Schraven, B.,
and Koretzky, G. A.
(1998)
J. Biol. Chem.
273,
25789-25795
|
| 61.
|
Liu, J.,
Kang, H.,
Raab, M.,
da Silva, A. J.,
Kraeft, S. K.,
and Rudd, C. E.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
8779-8784
|
| 62.
|
Anafi, M.,
Kiefer, F.,
Gish, G. D.,
Mbamalu, G.,
Iscove, N. N.,
and Pawson, T.
(1997)
J. Biol. Chem.
272,
27804-27811
|
| 63.
|
da Silva, A. J.,
Raab, M.,
Li, Z.,
and Rudd, C. E.
(1997)
Biochem. Soc. Trans.
25,
361-366
|
| 64.
|
Waters, S. B.,
Holt, K. H.,
Ross, S. E.,
Syu, L. J.,
Guan, K. L.,
Saltiel, A. R.,
Koretzky, G. A.,
and Pessin, J. E.
(1995)
J. Biol. Chem.
270,
20883-20886
|
| 65.
|
Holt, K. H.,
Waters, S. B.,
Okada, S.,
Yamauchi, K.,
Decker, S. J.,
Saltiel, A. R.,
Motto, D. G.,
Koretzky, G. A.,
and Pessin, J. E.
(1996)
J. Biol. Chem.
271,
8300-8306
|
| 66.
|
Zhao, H.,
Okada, S.,
Pessin, J. E.,
and Koretzky, G. A.
(1998)
J. Biol. Chem.
273,
12061-12067
|
| 67.
|
Langlois, W. J.,
Sasaoka, T.,
Saltiel, A. R.,
and Olefsky, J. M.
(1995)
J. Biol. Chem.
270,
25320-25323
|
| 68.
|
Klarlund, J. K.,
Cherniack, A. D.,
McMahon, M.,
and Czech, M. P.
(1996)
J. Biol. Chem.
271,
16674-16677
|
| 69.
|
Zhao, H.,
Li, Y. Y.,
Fucini, R. V.,
Ross, S. E.,
Pessin, J. E.,
and Koretzky, G. A.
(1997)
J. Biol. Chem.
272,
21625-21634
|
| 70.
|
Buday, L.,
Warne, P. H.,
and Downward, J.
(1995)
Oncogene
11,
1327-1331
|
| 71.
|
Zhou, G.,
Lee, S. C.,
Yao, Z.,
and Tan, T. H.
(1999)
J. Biol. Chem.
274,
13133-13138
|
| 72.
|
Dan, I.,
Watanabe, N. M.,
and Kusumi, A.
(2001)
Trends Cell Biol.
11,
220-230
|
| 73.
|
Kyriakis, J. M.
(1999)
J. Biol. Chem.
274,
5259-5262
|
| 74.
|
Su, B.,
Jacinto, E.,
Hibi, M.,
Kallunki, T.,
Karin, M.,
and Ben-Neriah, Y.
(1994)
Cell
77,
727-736
|
| 75.
|
Hehner, S. P.,
Hofmann, T. G.,
Dienz, O.,
Droge, W.,
and Schmitz, M. L.
(2000)
J. Biol. Chem.
275,
18160-18171
|
| 76.
|
Schultz, J.,
Milpetz, F.,
Bork, P.,
and Ponting, C. P.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
5857-5864
|
| 77.
|
Shapiro, V. S.,
Mollenauer, M. N.,
Greene, W. C.,
and Weiss, A.
(1996)
J. Exp. Med.
184,
1663-1669
|
| 78.
|
Salvesen, G. S.,
and Dixit, V. M.
(1997)
Cell
91,
443-446
|
| 79.
|
Hu, M. C.,
Wang, Y.,
Qiu, W. R.,
Mikhail, A.,
Meyer, C. F.,
and Tan, T. H.
(1999)
Oncogene
18,
5514-5524
|
| 80.
|
Arnold, R.,
Liou, J.,
Drexler, H. C.,
Weiss, A.,
and Kiefer, F.
(2001)
J. Biol. Chem.
276,
14675-14684
|
| 81.
|
Tsuji, S.,
Okamoto, M.,
Yamada, K.,
Okamoto, N.,
Goitsuka, R.,
Arnold, R.,
Kiefer, F.,
and Kitamura, D.
(2001)
J. Exp. Med.
194,
529-539
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Shen, J. Lau, M. Zhu, J. Zou, D. Fuller, Q.-j. Li, and W. Zhang
The importance of Src homology 2 domain-containing leukocyte phosphoprotein of 76 kilodaltons sterile-{alpha} motif domain in thymic selection and T-cell activation
Blood,
July 2, 2009;
114(1):
74 - 84.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Alzabin, N. Bhardwaj, F. Kiefer, S. Sawasdikosol, and S. Burakoff
Hematopoietic Progenitor Kinase 1 Is a Negative Regulator of Dendritic Cell Activation
J. Immunol.,
May 15, 2009;
182(10):
6187 - 6194.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Sawasdikosol, S. Pyarajan, S. Alzabin, G. Matejovic, and S. J. Burakoff
Prostaglandin E2 Activates HPK1 Kinase Activity via a PKA-dependent Pathway
J. Biol. Chem.,
November 30, 2007;
282(48):
34693 - 34699.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Abudula, A. Grabbe, M. Brechmann, C. Polaschegg, N. Herrmann, I. Goldbeck, K. Dittmann, and J. Wienands
SLP-65 Signal Transduction Requires Src Homology 2 domain-mediated Membrane Anchoring and a Kinase-independent Adaptor Function of Syk
J. Biol. Chem.,
September 28, 2007;
282(39):
29059 - 29066.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. D. Bartolo, B. Montagne, M. Salek, B. Jungwirth, F. Carrette, J. Fourtane, N. Sol-Foulon, F. Michel, O. Schwartz, W. D. Lehmann, et al.
A novel pathway down-modulating T cell activation involves HPK-1-dependent recruitment of 14-3-3 proteins on SLP-76
J. Exp. Med.,
March 19, 2007;
204(3):
681 - 691.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Grabbe and J. Wienands
Human SLP-65 isoforms contribute differently to activation and apoptosis of B lymphocytes
Blood,
December 1, 2006;
108(12):
3761 - 3768.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. C. Bunnell, A. L. Singer, D. I. Hong, B. H. Jacque, M. S. Jordan, M.-C. Seminario, V. A. Barr, G. A. Koretzky, and L. E. Samelson
Persistence of cooperatively stabilized signaling clusters drives T-cell activation.
Mol. Cell. Biol.,
October 1, 2006;
26(19):
7155 - 7166.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. J. Hassan, S. J. Simmonds, N. G. Clarkson, S. Hanrahan, M. J. Puklavec, M. Bomb, A. N. Barclay, and M. H. Brown
CD6 Regulates T-Cell Responses through Activation-Dependent Recruitment of the Positive Regulator SLP-76.
Mol. Cell. Biol.,
September 1, 2006;
26(17):
6727 - 6738.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Abtahian, N. Bezman, R. Clemens, E. Sebzda, L. Cheng, S. J. Shattil, M. L. Kahn, and G. A. Koretzky
Evidence for the Requirement of ITAM Domains but Not SLP-76/Gads Interaction for Integrin Signaling in Hematopoietic Cells.
Mol. Cell. Biol.,
September 1, 2006;
26(18):
6936 - 6949.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Silverman, J. Shoag, J. Wu, and G. A. Koretzky
Disruption of SLP-76 Interaction with Gads Inhibits Dynamic Clustering of SLP-76 and Fc{varepsilon}RI Signaling in Mast Cells.
Mol. Cell. Biol.,
March 1, 2006;
26(5):
1826 - 1838.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-S. Yang, C. P. Matthews, T. Clair, Q. Wang, A. R. Baker, C.-C. H. Li, T.-H. Tan, and N. H. Colburn
Tumorigenesis Suppressor Pdcd4 Down-Regulates Mitogen-Activated Protein Kinase Kinase Kinase Kinase 1 Expression To Suppress Colon Carcinoma Cell Invasion
Mol. Cell. Biol.,
February 15, 2006;
26(4):
1297 - 1306.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Jordan, J. Sadler, J. E. Austin, L. D. Finkelstein, A. L. Singer, P. L. Schwartzberg, and G. A. Koretzky
Functional Hierarchy of the N-Terminal Tyrosines of SLP-76
J. Immunol.,
February 15, 2006;
176(4):
2430 - 2438.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Han, J.-W. Shui, X. Zhang, B. Zheng, S. Han, and T.-H. Tan
HIP-55 Is Important for T-Cell Proliferation, Cytokine Production, and Immune Responses
Mol. Cell. Biol.,
August 15, 2005;
25(16):
6869 - 6878.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Arnold, I. M. Patzak, B. Neuhaus, S. Vancauwenbergh, A. Veillette, J. Van Lint, and F. Kiefer
Activation of Hematopoietic Progenitor Kinase 1 Involves Relocation, Autophosphorylation, and Transphosphorylation by Protein Kinase D1
Mol. Cell. Biol.,
March 15, 2005;
25(6):
2364 - 2383.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Wang, F. E. McCann, J. D. Gordan, X. Wu, M. Raab, T. H. Malik, D. M. Davis, and C. E. Rudd
ADAP-SLP-76 Binding Differentially Regulates Supramolecular Activation Cluster (SMAC) Formation Relative to T Cell-APC Conjugation
J. Exp. Med.,
October 18, 2004;
200(8):
1063 - 1074.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Lewitzky, M. Harkiolaki, M.-C. Domart, E. Y. Jones, and S. M. Feller
Mona/Gads SH3C Binding to Hematopoietic Progenitor Kinase 1 (HPK1) Combines an Atypical SH3 Binding Motif, R/KXXK, with a Classical PXXP Motif Embedded in a Polyproline Type II (PPII) Helix
J. Biol. Chem.,
July 2, 2004;
279(27):
28724 - 28732.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Utting, B. J. Sedgmen, T. H. Watts, X. Shi, R. Rottapel, A. Iulianella, D. Lohnes, and A. Veillette
Immune Functions in Mice Lacking Clnk, an SLP-76-Related Adaptor Expressed in a Subset of Immune Cells
Mol. Cell. Biol.,
July 1, 2004;
24(13):
6067 - 6075.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Imamura, T. Katahira, and D. Kitamura
Identification and Characterization of a Novel BASH N Terminus-associated Protein, BNAS2
J. Biol. Chem.,
June 18, 2004;
279(25):
26425 - 26432.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. N. Wu, M. S. Jordan, M. A. Silverman, E. J. Peterson, and G. A. Koretzky
Differential Requirement for Adapter Proteins Src Homology 2 Domain-Containing Leukocyte Phosphoprotein of 76 kDa and Adhesion- and Degranulation-Promoting Adapter Protein in Fc{epsilon}RI Signaling and Mast Cell Function
J. Immunol.,
June 1, 2004;
172(11):
6768 - 6774.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. L. Singer, S. C. Bunnell, A. E. Obstfeld, M. S. Jordan, J. N. Wu, P. S. Myung, L. E. Samelson, and G. A. Koretzky
Roles of the Proline-rich Domain in SLP-76 Subcellular Localization and T Cell Function
J. Biol. Chem.,
April 9, 2004;
279(15):
15481 - 15490.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Le Bras, I. Foucault, A. Foussat, C. Brignone, O. Acuto, and M. Deckert
Recruitment of the Actin-binding Protein HIP-55 to the Immunological Synapse Regulates T Cell Receptor Signaling and Endocytosis
J. Biol. Chem.,
April 9, 2004;
279(15):
15550 - 15560.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Katzav
Vav1: an oncogene that regulates specific transcriptional activation of T cells
Blood,
April 1, 2004;
103(7):
2443 - 2451.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kettner, V. Pivniouk, L. Kumar, H. Falet, J.-S. Lee, R. Mulligan, and R. S. Geha
Structural Requirements of SLP-76 in Signaling via the High-Affinity Immunoglobulin E Receptor (Fc{varepsilon}RI) in Mast Cells
Mol. Cell. Biol.,
April 1, 2003;
23(7):
2395 - 2406.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. R. Salomon, S. B. Ficarro, L. M. Brill, A. Brinker, Q. T. Phung, C. Ericson, K. Sauer, A. Brock, D. M. Horn, P. G. Schultz, et al.
Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry
PNAS,
January 21, 2003;
100(2):
443 - 448.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Mizuno, Y. Tagawa, K. Mitomo, N. Watanabe, T. Katagiri, M. Ogimoto, and H. Yakura
Src Homology Region 2 Domain-Containing Phosphatase 1 Positively Regulates B Cell Receptor-Induced Apoptosis by Modulating Association of B Cell Linker Protein with Nck and Activation of c-Jun NH2-Terminal Kinase
J. Immunol.,
July 15, 2002;
169(2):
778 - 786.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|